While at Johnson & Johnson, Coradini held a variety of senior leadership positions. Acting as President of various subsidiaries of J&J, including Lifescan, Cordis Endovascular, and Cardiovations (Ethicon), Coradini was the head of business development of the Medical Devices & Diagnostics Group. Most recently he sat as President of New Ventures for the Johnson & Johnson Consumer Group of Companies, overseeing the OrthoNeutrogena division, now known as Ortho Dermatologics after being acquired by Valeant International.
“We are thankful for Joseph’s leadership over the past nine years as the company has undergone a successful transformation from product development, to FDA Approval, to early commercial launch of MelaFind(R) in the US and Germany,” stated Coradini. “The Board and I believe in the technology as a major advance for dermatologists in their fight against Melanoma. It is our intent to work closely with these physicians to succeed. We wish Joseph the best in the next phase of his career.”
Resulting from these recent changes, David Stone who has served as Lead Independent Director will assume the role of Chairman of the board. In addition he will lead the search for Gulfo’s replacement.
MELA Sciences is currently focused on the commercialization of FDA-approved MelaFind(R). To learn more, visit www.melasciences.com.
About MissionIR
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Sign up for “The Mission Report” at www.MissionIR.com
Please see disclaimer on the MissionIR website
http://www.missionir.com/disclaimer.html
